G-Lomustin 10 mg
Lomustine
Category: Capsule
Manufacturer: Gonoshasthaya Pharmaceuticals Ltd.
Gonoshasthaya Pharmaceuticals Ltd.
Allopathic
MFG. Licence No. Biological
117
MFG. Licence No. Non-Biological
381
Address
Nayarhat, Savar, Dhaka
Price: 63.0 ৳
Capsule
Medicine Selling service is not available yet.
Uses of G-Lomustin:
- Brain tumor
- Lung cancer
- Hodgkin’s disease
- Malignant melanoma
Brain tumours, Hodgkin's disease, Lung cancer, Malignant melanoma
Pregnancy and lactation.
How to use
Lomustine:
Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it.
Lomustine is to be taken empty stomach.
Administration:
Should be taken on an empty stomach. Take on an empty stomach. May be taken at bedtime to reduce occurrence of nausea.
Adult Dose:
Oral
Brain tumours; Hodgkin's disease, resistant or relapsed; Malignant melanoma; Lung cancer
Adult: 100-130 mg/m2 as a single dose every 6 wk. Adjust dose according to platelet and leukocyte counts.
Compromised marrow function: 100 mg/m2 as a single dose every 6 wk.
Child Dose:
Oral
Brain tumours; Hodgkin's disease, resistant or relapsed; Malignant melanoma; Lung cancer
Child: 75-150 mg/m2 as a single dose every 6 wk. Readjust dose according to platelet and leukocyte counts.
Renal Dose:
Renal impairment:
CrCl (ml/min) Dosage Recommendation
10-50 Admin 75% of normal dose.
<10 Admin 25-50% of normal dose.
Increased levels/effects with CYP2D6 inhibitors.
Pregnancy and lactation.
Common
- Nausea
- Vomiting
- Stomatitis (Inflammation of the mouth)
- Hair loss
- Decreased white blood cell count
>10%
Nausea (54%),Vomiting (54%)
1-10%
Neurotoxicity,Myelosuppression (delayed 4-5 weeks)
Frequency Not Defined
Ataxia,Lethargy,Disorientation,Stomatitis,Mucositis,Pulmonary fibrosis (rare),Pulmonary toxicity,Elevated LFTs,Leukemia,Renal toxicity,Hepatic toxicity,Infertility,Alopecia,Optic atrophy (rare)
Potentially Fatal: Delayed bone marrow suppression and permanent marrow damage following prolonged use.
Precaution:
Monitor CBC with differential platelet count wkly for at least 6 wk after a dose. Periodically perform pulmonary function studies and LFTs.
Lactation: Unknown if metabolites present in breast milk; avoid nursing during treatment and for 2 weeks after final dose
Lomustine inhibits the synthesis of DNA and RNA via alkylation although carbamoylation and modification of cellular proteins may also be involved.
Samm Care